Followed by gradual optimization of the therapeutic vector, a clinically applicable lentiviral vector where the RPS19 gene was driven by a cellular promoter, was shown to achieve both safety and efficacy in rescuing anemia and promote normal hematopoiesis in mouse and human RPS19-deficient models in 2021 [5]. Here, RPS19 is linked to anemia.